Fig. 3From: Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trialTornado diagram for sensitivity analysis results. CR, complete remission; ICER, incremental cost-effectiveness ratio; PR, partial remission; SCT, stem cell transplantation; SD, stable disease; OS, overall survival; PD, progressive disease; USD, US dollarsBack to article page